Successfully Launched last days of December 2016, this hasn't seen much notice here, hence this comment FWIW.
158 is a mighty high price for AIM ( for me nothing over 50p unless I'm squeezed ), esp with no previous history . . . their Website is full of what they could achieve, but little precise details.
++I used "Parallel" because at a glance this appears to be an orphan child of the combined attempts by OXB ( Oxford Biomedica is fully listed, yet barely managing 4p - DYOR ) and AIM,Proteome which has for many years attempted to interest the likes of NHS into using BioMarkers ( DYOR ). I hold both in hope.
Sadly neither of these established Co's has managed to move into profit ( or IMHO anything that looks good over 10 years and counting ), so I wonder how this co. [ AIM: OBD ], can gain a market price of 158p, raising about £20m . . . while shouting over very little.... Didn't the MM's do well?

Good luck to all who sail in her; I shall look with interest, if ever there is some real News to digest. An AGM in London, after 11am would assist - and maybe someone from the Press will attend also. Yippee.